Skip to main content
Publications
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Sauchelli S, Jimenez-Murcia S, Sanchez I, Riesco N, Custal N, Fernandez-Garcia JC, Garrido-Sanchez L, Tinahones FJ, Steiger H, Israel M, Banos RM, Botella C, de la Torre R, Fernandez-Real JM, Ortega FJ, Fruhbeck G, Granero R, Tarrega S, Crujeiras AB, Rodriguez A, Estivill X, Beckmann JS, Casanueva FF, Menchon JM, Fernandez-Aranda F. Orexin and sleep quality in anorexia nervosa: clinical relevance and influence on treatment outcome. Psychoneuroendocrinology. 2016 Mar;65:102-8. doi: 10.1016/j.psyneuen.2015.12.014
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.